Regulatory filing

AMGEN INC disclosed a material cybersecurity incident

What the company disclosed

In July 2026, Amgen Inc. (the "Company") identified unauthorized activity involving data stored in cloud environments hosted by third-party cloud service providers. Upon detecting the activity, the Company activated its cybersecurity response plan, implemented containment measures, and engaged independent cybersecurity forensic experts.

The Company has since learned that some of its data, including proprietary data, patient protected health information, and other information, has been exfiltrated from these cloud environments. To date, the Company has not identified any impact to its products, manufacturing operations, or financial reporting systems, or to the Company's ability to meet patient needs. The investigation remains ongoing. The Company continues to assess whether, and/or the extent to which, patient, confidential business information, intellectual property, research and development, or other information may have been accessed, acquired, or exfiltrated and to evaluate the potential impact of the incident on the Company. On July 29, 2026, in connection with our evaluation of the volume of the files that appear to have been impacted and the potential that the types of information in such files could be sensitive, the Company determined that this incident is material. The Company believes, as of the date of this Current Report on Form 8-K, that the incident is not reasonably likely to have a material impact on the Company's financial condition or results of operations.

The Company takes its obligation to safeguard privacy and security of its patients' data very seriously. The Company continues to evaluate applicable regulatory and legal notification requirements and will make all required notifications based on its findings, including to impacted patients.

To the extent any information required by Item 1.05(a) of Form 8-K was not determined or was unavailable at the time of this filing, the Company will amend this Current Report on Form 8-K as such information is determined or becomes available.

Quoted from the company’s own Form 8-K, Item 1.05, as filed with the US Securities and Exchange Commission. SEC filings are works of the US federal government and are in the public domain.

The record

Identity
AMGEN INCidentified by its SEC Central Index Key (0000318154)
Records affected
Records not disclosed
Sector
Biological Products, (No Diagnostic Substances)SIC 2836, from the company’s own filing
Occurred
2026-07-01
Disclosed
2026-07-31
First recorded here
2026-09-09

Sources (2)

More than one source reported this. Agreement across independent sources is the strongest signal available, and the order below is the order they reported.

  1. SEC EDGARFirst reported

    2026-07-31

  2. 2026-08-17